Insmed’s PhII smokes and sputters, but researchers herald enough surprisingly positive data to roar on Wall Street
There was plenty not to like in Insmed’s Phase II readout of an anti-inflammatory drug dubbed INS1007.
The dose response didn’t pan out and in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
